Recent Posts
- Hikma v. Vanda: Oral Argument Recap
- Teva v. Lilly should not be read as creating a new 112 rule for method of use claims
- Should ANDA filers be using the PTAB to mount early challenges to OB patents?
- Switching to WordPress
- Judge Hughes concurrence highlights post grant review appeal standing issue for pharma cases
Category: Conferences
-
The 2010 BIO International Convention is in Chicago this week and Orange Book Blog will be there covering it all. I'll be hanging out at the MBHB booth on Tuesday from 5-6:30 and Thursday from 3-5. The rest of the time, I'll be meeting with clients, hearing talks from industry leaders, checking out the BIO Exhibition and BIOPark, and going…
-
American Conference Institute’s 4th Annual “Paragraph IV Disputes" conference will take place in New York City on April 27–28. I am looking forward to speaking at the conference in a session entitled “Recent Decisions Impacting Paragraph IV Challenges and Motion Practice”. My presentation will be about recent judicial decisions concerning declaratory judgment jurisdiction and method-of-treatment patents. A highlight of the conference will…
-
American Conference Institute is hosting a special 10th Anniversary Edition of its annual "Maximizing Pharmaceutical Patent Life Cycles" conference on October 7th and 8th in New York. According to ACI, this is "the one and only event that consistently allows brand name and generic drug makers to benchmark their companies' current strategies and tactics against…
-
American Conference Institute's popular "FDA Boot Camp" conference is coming to Chicago next week, July 21-22, and to Boston on September 15-16. The conference is billed as "basic training for products liability and patent lawyers." Presentations likely of most interest to Orange Book Blog readers include: The Basics: Understanding and Working with the FDA and…
-
The Federal Trade Commission is hosting a roundtable entitled "Competition Issues Involving Follow-On Biologic Drugs," Friday, November 21, at its headquarters in Washington. Speakers include industry leaders, government officials, outside counsel and others. The agenda includes the following presentations: Welcoming remarks, FTC Commissioner Pamela Jones Harbour Opening remarks, Rachel Behrman, FDA: "How Do Biologic Drugs Differ…
-
American Conference Institute is presenting its first-ever "Paragraph IV On Trial" Conference, November 19-20 in New York. This is a unique conference, with the format of a mock trial in a Hatch-Waxman case. ACI states: "Structured as an actual trial based on an ANDA filing involving a compound and a formulation patent, our experienced faculty…
-
BNA Legal & Business Edge is presenting a conference entitled "Pharmaceutical Patent Laws: A Prescription for Success in Challenging Times, November 12 in Arlington, VA. According to BNA, this will be a "fast-paced conference on the latest developments and changes in pharmaceutical patent law." Here's the agenda: Morning Keynote Address: Inequitable Conduct "Pay for Delay" and Other…
-
C5 is presenting a conference next month entitled “EU Pharma Law and Regulation.” It will take place November 4-5 in Geneva, Switzerland. According to C5, “From the EU Pharma Sector Inquiry to recent parallel trade cases, the continued growth of counterfeiting, multiple options for extending product exclusivity amidst dwindling product pipelines and blockbusters coming off-patent,…
-
Last week, I gave a talk about non-patent exclusivity at ACI's FDA Boot Camp conference in Boston. The talk covered new chemical entity (5-year) exclusivity; new clinical trial (3-year) exclusivity; orphan drug exclusivity; pediatric exclusivity; and generic drug (180-day) exclusivity. You can download a copy of my slides here. In June, I gave a talk about…
-
On October 15-16 in Philadelphia, the Center for Business Intelligence will hold a conference entitled "Pharmaceutical Congress on Paragraph IV Disputes: Navigating Regulations and Enforcement Trends to Increase Preparedness and Optimize Paragraph IV Strategies." CBI provides its top five reasons to attend: To hear the FTC's stance on antitrust and acceptable settlement strategies To learn to…
Orange Book Blog 